ECSP14013302A - Composiciones de yodo-povidona estable - Google Patents

Composiciones de yodo-povidona estable

Info

Publication number
ECSP14013302A
ECSP14013302A ECSP14013302A ECSP14013302A EC SP14013302 A ECSP14013302 A EC SP14013302A EC SP14013302 A ECSP14013302 A EC SP14013302A EC SP14013302 A ECSP14013302 A EC SP14013302A
Authority
EC
Ecuador
Prior art keywords
compositions
povidona
stable iodine
pvp
iodine
Prior art date
Application number
Other languages
English (en)
Inventor
Bo Liang
Joseph A Capriotti
C Michael Samson
Jason Stein
Michael Weiser
Original Assignee
Foresight Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47883771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013302(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Foresight Biotherapeutics Inc filed Critical Foresight Biotherapeutics Inc
Publication of ECSP14013302A publication Critical patent/ECSP14013302A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A01N59/12—Iodine, e.g. iodophors; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulgan en la presente composiciones que contienen PVP-I, así como también métodos para fabricar dichas composiciones, que proporcionan estabilidad confiable para preparaciones de PVP-I, que incluyen preparaciones que comprenden PVP-I y uno o más componentes adicionales
ECSP14013302 2011-09-16 2014-04-11 Composiciones de yodo-povidona estable ECSP14013302A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161535667P 2011-09-16 2011-09-16

Publications (1)

Publication Number Publication Date
ECSP14013302A true ECSP14013302A (es) 2014-05-31

Family

ID=47883771

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013302 ECSP14013302A (es) 2011-09-16 2014-04-11 Composiciones de yodo-povidona estable

Country Status (16)

Country Link
US (1) US20150164939A1 (es)
EP (2) EP3556372A1 (es)
JP (3) JP6539444B2 (es)
KR (2) KR20140077900A (es)
CN (2) CN103889218A (es)
AR (1) AR087857A1 (es)
AU (2) AU2012308424B2 (es)
BR (1) BR112014005487A2 (es)
CA (1) CA2847364C (es)
CL (2) CL2014000592A1 (es)
CO (1) CO6930368A2 (es)
EC (1) ECSP14013302A (es)
MX (1) MX2014002679A (es)
PE (1) PE20141676A1 (es)
TW (4) TW201808311A (es)
WO (1) WO2013040347A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX360666B (es) * 2011-05-12 2018-11-13 Foresight Biotherapeutics Inc Composiciones de yodopovidona estables con antiinflamatorios esteroides y no esteroides.
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3365022A4 (en) * 2015-10-25 2019-07-24 IVIEW Therapeutics, Inc. PHARMACEUTICAL FORMULATIONS WITH IN-SITU FORMULATION
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
JP6255134B1 (ja) * 2016-11-02 2017-12-27 ヴェローチェ・バイオファーマ・エルエルシー 耳炎の治療のための組成物および方法
PL3612228T3 (pl) * 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
CN110559175A (zh) * 2019-08-27 2019-12-13 陈文龙 一种结膜囊消毒溶液及其使用方法和装置
US20230181625A1 (en) * 2021-12-14 2023-06-15 Harrow Ip, Llc Method and composition for treating infectious conjunctivitis
KR102859862B1 (ko) * 2023-03-31 2025-09-16 주식회사 퍼슨헬스케어 창상피복용 조성물 및 그 제조 방법
WO2025243071A1 (en) 2024-05-22 2025-11-27 Apex Laboratories Private Limited A medicinal composition of povidone iodine and a biopolymer and a process of making it

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886268A (en) 1972-05-30 1975-05-27 Synergistics Iodophor-steroid compound pharmaceutical compositions
US4113857A (en) 1977-05-16 1978-09-12 The Purdue Frederick Company Process for the preparation of iodophor compounds and methods for stabilizing iodophor pharmaceutical compositions containing the same
US4954351A (en) * 1983-03-02 1990-09-04 Euroceltique S.A. Method of producing standardized povidone iodine preparations and such preparations
US4996048A (en) 1988-11-30 1991-02-26 Euroceltique, S.A. Stabilizing packaged iodophor and minimizing leaching of iodine through packaging
US5232692A (en) * 1989-04-28 1993-08-03 Research And Education Institute, Inc. Povidone-iodine neonatal ophthalmic antimicrobial prophylactic agent
US5126127A (en) 1991-07-16 1992-06-30 Euroceltique, S.A. Stabilized PVP-I solutions
IL135222A (en) * 2000-03-22 2005-06-19 Univ Ben Gurion Compositions containing molecular iodine
PL373787A1 (en) * 2002-05-03 2005-09-19 Alcon Inc. Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
US20060280809A1 (en) * 2005-06-14 2006-12-14 Leshchiner Adele K Anti-infective iodine based compositions for otic and nasal use
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US20090092574A1 (en) * 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
EP2229174A1 (en) * 2007-12-04 2010-09-22 Novagali Pharma S.A. Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders
US20090263345A1 (en) * 2008-01-28 2009-10-22 Foresight Biotherapeutics, Inc. Otic compositions for the treatment of infections of the internal and external ear in mammals
CA2716110A1 (en) * 2008-02-21 2009-08-27 Tim Mcnamara Ophthalmic nsaids as adjuvants
AU2009258145A1 (en) * 2008-06-12 2009-12-17 Foresight Biotherapeutics, Inc. Povidone iodine, a novel alternative preservative for ophthalmic compositions
JP2010059058A (ja) * 2008-09-01 2010-03-18 Kowa Co 鎮痛・抗炎症剤含有外用剤
JP5410071B2 (ja) * 2008-10-07 2014-02-05 久光製薬株式会社 エステル化抑制剤及びエステル化抑制方法
TWI620569B (zh) * 2009-12-15 2018-04-11 遠景生物製藥股份有限公司 無刺激性眼用聚乙烯吡咯啶酮-碘組成物
MX360666B (es) * 2011-05-12 2018-11-13 Foresight Biotherapeutics Inc Composiciones de yodopovidona estables con antiinflamatorios esteroides y no esteroides.

Also Published As

Publication number Publication date
US20150164939A1 (en) 2015-06-18
CL2017001952A1 (es) 2018-03-16
KR20190099084A (ko) 2019-08-23
EP3556372A1 (en) 2019-10-23
PE20141676A1 (es) 2014-11-06
TW201325601A (zh) 2013-07-01
CL2014000592A1 (es) 2014-11-03
MX2014002679A (es) 2014-04-25
CO6930368A2 (es) 2014-04-28
AU2016204700B2 (en) 2018-03-22
TW202023575A (zh) 2020-07-01
JP2020007324A (ja) 2020-01-16
JP6539444B2 (ja) 2019-07-03
AR087857A1 (es) 2014-04-23
CA2847364C (en) 2020-08-25
TW202126313A (zh) 2021-07-16
CN103889218A (zh) 2014-06-25
CN107595879A (zh) 2018-01-19
EP2755477A4 (en) 2015-05-06
AU2012308424A1 (en) 2013-05-02
KR20140077900A (ko) 2014-06-24
TW201808311A (zh) 2018-03-16
JP2014526514A (ja) 2014-10-06
JP2018024689A (ja) 2018-02-15
EP2755477A1 (en) 2014-07-23
WO2013040347A1 (en) 2013-03-21
CA2847364A1 (en) 2013-03-21
AU2016204700A1 (en) 2016-07-21
AU2012308424B2 (en) 2016-08-04
BR112014005487A2 (pt) 2017-03-21

Similar Documents

Publication Publication Date Title
MX2014002679A (es) Composiciones estables de yodo-povidona.
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
BR112014017799A8 (pt) Compostos inibidores de metaloenzima
UY34765A (es) Compuestos novedosos.
CL2015001486A1 (es) Composición que comprende agentes de control biológico.
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CO6680675A2 (es) Tidiazoles substituidos y composiciones pesticidas que los contienen
CR20150250A (es) Nuevos derivados de piridina
MX372691B (es) Pirrolobenzodiazepinas y conjugados de las mismas.
UY34824A (es) Nucleósidos de espirooxetano de uracilo
UY34697A (es) Métodos para preparar análogos de nucleótidos
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
IN2015DN03029A (es)
UY33936A (es) Derivados de fluoro-piridinona útiles como agentesantibacterianos.
UY34817A (es) Tienopirimidinas
AR093645A1 (es) Una formulacion estabilizada de pemetrexed
EA201590887A1 (ru) Композиция
CR20150440A (es) Nuevos derivados de piridina
CR20150133A (es) Amino-quinolinas como inhibidores de cinasa
UY33549A (es) Quinolil aminas como agentes inhibidores de las quinasas
BR112013025866A2 (pt) formulações com viscosidade reduzida
CR20150257A (es) Derivados de n-(piridin-2-il)pirimidin-4-amina que contiene un grupo sulfoximina
BR112014029264A2 (pt) microcápsulas contendo um oxidável ativa, e um processo para a preparação do mesmo
UY34842A (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4